Can Body Composition Help us Better Understand Outcomes in People with Lupus?
IRB Number: 2017-1061
March 11, 2019
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
Co-Investigators
- Jessica R. Berman, MD
- John A. Carrino, MD, MPH
- Jackie Finik
- Kyriakos A. Kirou, MD, DSc, FACP
- Sarah B. Lieber, MD, MS
- Stephen A. Paget, MD, FACP, FACR
- Lisa R. Sammaritano, MD
- Dina Sheira
Summary
Number of patients: 70
Enrollment period: Ongoing; anticipated completion 6/30/19
Duration of follow-up: 1 year
Inclusion/Exclusion Criteria
Inclusion criteria:
- Women 18-70 years old followed at HSS
- Meet American College of Rheumatology criteria for systemic lupus erythematosus
Exclusion criteria:
- Pregnancy, active malignancy, on dialysis
- Status post recent surgery or injury limiting participation in performance-based measures
- Severe flare based on standard criteria
- Presence of overlap autoimmune condition
- Unable to complete surveys in English
Contact Information
Sarah Lieber, MD
liebers@hss.edu
212.774.2482